Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This case report suggests that hair loss may be a potential adverse effect of rivaroxaban, though it is not listed in the product characteristics.

In this study, researchers investigated a new local drug delivery system using glycol chitosan hydrogel and doxorubicin (GC10/DOX) for thyroid cancer in mice, finding it produced a stronger antitumor effect compared to conventional treatment methods.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

In this study, sorafenib's common adverse events, like a hand-foot syndrome and diarrhea, were observed in distinct temporal and tissue distribution patterns, revealing new relationships among effects.

This case report describes a patient with painful skin lesions during sorafenib treatment whose symptoms improved after receiving photodynamic therapy, suggesting it might help manage similar refractory skin toxicity cases.

This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².

This study suggests that certain nutraceuticals may enhance the inhibitory effects of tamoxifen on estrogen in breast cancer cells and potentially offer protective benefits for hair growth in patients undergoing endocrine therapy.

This study found that both Lactobacillus casei extract and Newcastle disease virus significantly reduced cell viability and induced apoptosis in human colorectal cancer cells, suggesting these agents could complement standard chemotherapy and radiotherapy after further clinical trials.

This study found that, among patients with NSCLC after EGFR-TKI failure, pemetrexed is as effective as docetaxel but has fewer side effects, suggesting it may be a suitable salvage chemotherapy option.

In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.

This review highlights that vitexin, a natural flavonoid derived from plants like mung bean, modulates critical cellular processes involved in cancer progression, suggesting its potential as a multi-target anticancer treatment in preclinical studies.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.

This article discusses a case of delayed onset perforating folliculitis linked to the use of sorafenib, but it reports no new clinical results.

In a preclinical mouse model, this study found that early treatment with the selective SYK inhibitor entospletinib significantly improved survival rates and clinical outcomes for graft-versus-host disease after hematopoietic stem cell transplantation compared to placebo.

In this case report, a novel Ayurvedic preparation of Catharanthus roseus, used alongside conventional chemotherapy, was associated with tumor stability and improved general health in a patient with advanced esophageal squamous cell carcinoma.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This review discusses nanoparticle systems for cancer treatment and reports no new clinical results; the authors emphasize their potential to reduce systemic toxicity and call for further development.

This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.

This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.

In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.

This article suggests using nicotinamide and minoxidil as potassium channel activators to target solid tumors, but reports no new clinical results and calls for further research.

Ivarmacitinib effectively regrows hair in severe alopecia areata.